Greenland Mines Seeks Shareholder Approval for Over 1600% Potential Dilution to Avoid Nasdaq Delisting
GRML sits 43% above its 52-week low of $0.21.
Summary
Greenland Mines Ltd is seeking shareholder approval for a massive issuance of over 2 billion shares, which would result in over 1600% dilution, to comply with Nasdaq listing rules and avoid delisting. This is in addition to a significant expansion of its equity incentive plan.
Key Events · Financing and Capital Events · GRML
-
Massive Share Issuance Proposal
Shareholders are asked to approve the issuance of up to 2,040,038,760 shares of common stock upon conversion of Series C Preferred Stock (issued for the March 4, 2026 acquisition of Greenland Mines Corp.) and up to 34,551,939 shares upon exercise of private Warrants. This represents a potential dilution of over 1600% relative to current outstanding shares, with the Series C conversion alone potentially comprising 94.4% of the new total outstanding shares.
-
Nasdaq Compliance Requirement
Approval of the share issuance is required by Nasdaq Listing Rule 5635. Failure to approve would prevent the company from issuing the shares and lead to delisting from the Nasdaq Stock Market, incurring substantial adverse consequences and requiring the company to call meetings every 90 days until approval is obtained.
-
Equity Incentive Plan Expansion
The company proposes to amend its 2024 Equity Incentive Plan to increase the number of shares available for issuance by 10,000,000, bringing the total to 20,000,000 shares. This would represent approximately 16.5% of the company's currently outstanding common stock, adding further significant dilution.
-
Special Meeting Scheduled
A Special Meeting of Stockholders will be held virtually on July 16, 2026, to vote on these proposals. This follows a previous PRE 14A filing on May 15, 2026, for a separate special meeting on June 18, 2026, to vote on a reverse stock split.
Analysis · GRML · Life Sciences
Greenland Mines Ltd is asking shareholders to approve the issuance of over 2 billion new shares, primarily for the conversion of Series C Preferred Stock issued in a recent acquisition. This represents a potential dilution of over 1600% for existing common stockholders. Approval is critical to avoid delisting from Nasdaq, which has already granted the company an extension to regain compliance. The company also seeks to significantly expand its equity incentive plan, adding further dilution. This comes amidst ongoing financial distress, going concern doubts, and a pending reverse stock split, highlighting the extreme measures the company is taking to maintain its listing and fund its strategic transformation.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 42% of the 419 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GRML was trading at $0.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $36.3M. The 52-week trading range was $0.21 to $3.91. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.